(Q37050163)

17 August 2017

1 reference

title

Prompt, aggressive BP lowering in high-risk patients (English)

1 reference

17 August 2017

Kenneth A Jamerson

1

1 reference

17 August 2017

Jan Basile

series ordinal

2

1 reference

17 August 2017

publication date

1 January 2008

1 reference

Journal of Clinical Hypertension

17 August 2017

published in

1 reference

17 August 2017

volume

10

1 reference

17 August 2017

issue

1 Suppl 1

1 reference

17 August 2017

page(s)

40-48

1 reference

Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure

17 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1524-6175.2007.08145.X

Diabetes and hypertension: epidemiology of the relationship and pathophysiology of factors associated with these comorbid conditions

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1524-6175.2007.08145.X

Is pulse pressure useful in predicting risk for coronary heart Disease? The Framingham heart study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1524-6175.2007.08145.X

2007 Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1524-6175.2007.08145.X

Management of high blood pressure in African Americans: consensus statement of the Hypertension in African Americans Working Group of the International Society on Hypertension in Blacks

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1524-6175.2007.08145.X

Preserving renal function in adults with hypertension and diabetes: a consensus approach. National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1524-6175.2007.08145.X

Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1524-6175.2007.08145.X

Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1524-6175.2007.08145.X

Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1524-6175.2007.08145.X

Cardiovascular prevention and blood pressure reduction: a quantitative overview updated until 1 March 2003.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1524-6175.2007.08145.X

Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1524-6175.2007.08145.X

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1524-6175.2007.08145.X

The management of hypertension in African Americans

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1524-6175.2007.08145.X

Determinants of blood pressure response to quinapril in black and white hypertensive patients: the Quinapril Titration Interval Management Evaluation trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1524-6175.2007.08145.X

Using angiotensin converting enzyme inhibitors in African-American hypertensives: a new approach to treating hypertension and preventing target-organ damage

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1524-6175.2007.08145.X

Systematic review and meta-analysis of ethnic differences in risks of adverse reactions to drugs used in cardiovascular medicine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1524-6175.2007.08145.X

Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus. Atherosclerosis Risk in Communities Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1524-6175.2007.08145.X

Diabetes, hypertension, and cardiovascular disease: an update

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1524-6175.2007.08145.X

Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1524-6175.2007.08145.X

Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1524-6175.2007.08145.X

Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1524-6175.2007.08145.X

Examination of lower targets for low-density lipoprotein cholesterol and blood pressure in diabetes--the Stop Atherosclerosis in Native Diabetics Study (SANDS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1524-6175.2007.08145.X

Rationale and design for the blood pressure intervention of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1524-6175.2007.08145.X

Prevalence, awareness, treatment, and control of hypertension among United States adults 1999-2004.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1524-6175.2007.08145.X

Racial disparities in hypertension prevalence, awareness, and management

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1524-6175.2007.08145.X

Combination therapy with diuretics: an evolution of understanding

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1524-6175.2007.08145.X

Achieving goal blood pressure in patients with type 2 diabetes: conventional versus fixed-dose combination approaches

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1524-6175.2007.08145.X

Initial angiotensin-converting enzyme inhibitor/calcium channel blocker combination therapy achieves superior blood pressure control compared with calcium channel blocker monotherapy in patients with stage 2 hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1524-6175.2007.08145.X

Efficacy of combination therapy for systolic blood pressure in patients with severe systolic hypertension: the Systolic Evaluation of Lotrel Efficacy and Comparative Therapies (SELECT) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1524-6175.2007.08145.X

Efficacy and tolerability of combination therapy with valsartan plus hydrochlorothiazide compared with amlodipine monotherapy in hypertensive patients with other cardiovascular risk factors: the VAST study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1524-6175.2007.08145.X

Tolerability and blood pressure-lowering efficacy of the combination of amlodipine plus valsartan compared with lisinopril plus hydrochlorothiazide in adult patients with stage 2 hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1524-6175.2007.08145.X

The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1524-6175.2007.08145.X

Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (A

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1524-6175.2007.08145.X

Efficacy of a fixed-dose combination of trandolapril-verapamil in patients with stage 2 hypertension inadequately controlled by monotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1524-6175.2007.08145.X

Amlodipine and valsartan combined and as monotherapy in stage 2, elderly, and black hypertensive patients: subgroup analyses of 2 randomized, placebo-controlled studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1524-6175.2007.08145.X

The pathophysiologic role of the brain renin-angiotensin system in stroke protection: clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1524-6175.2007.08145.X

Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1524-6175.2007.08145.X

Development of diabetes is retarded by ACE inhibition in hypertensive patients--a subanalysis of the Captopril Prevention Project (CAPPP).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1524-6175.2007.08145.X

Risk of new-onset diabetes in the Losartan Intervention For Endpoint reduction in hypertension study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1524-6175.2007.08145.X

The development of new-onset type 2 diabetes associated with choosing a calcium channel blocker compared to a diuretic or beta-blocker

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1524-6175.2007.08145.X

Imidapril, an angiotensin-converting enzyme inhibitor, improves insulin sensitivity by enhancing signal transduction via insulin receptor substrate proteins and improving vascular resistance in the Zucker fatty rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1524-6175.2007.08145.X

Angiotensin type-1 receptor blockade with losartan increases insulin sensitivity and improves glucose homeostasis in subjects with type 2 diabetes and nephropathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1524-6175.2007.08145.X

Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1524-6175.2007.08145.X

Effect of losartan on microalbuminuria in normotensive patients with type 2 diabetes mellitus. A randomized clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1524-6175.2007.08145.X

Primary Prevention of Cardiovascular Diseases in People With Diabetes Mellitus: A Scientific Statement From the American Heart Association and the American Diabetes Association

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1524-6175.2007.08145.X

Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1524-6175.2007.08145.X

10.1111/J.1524-6175.2007.08145.X

21 January 2018

Identifiers

DOI

1 reference

17 August 2017

1 reference